Answers are grounded in this paper and cite their sources.
Evaluates machine learning's effectiveness in predicting recurrence risk in early-stage NSCLC, suggesting improved postoperative management strategies.
e20053 Background: Recurrence risk after curative-intent surgery in early-stage (I–II) NSCLC remains heterogeneous. We developed and externally validated a machine-learning model to improve recurrence risk stratification for personalized postoperative management. Methods: We retrospectively evaluated a cohort of 724 patients with stage I–II NSCLC who underwent curative-intent resection. Recurrence was defined as radiologic and/or pathologic evidence of relapse, and a total of 52 patients experienced disease recurrence. A Random Forest (RF) classifier was trained using 11 routinely collected variables and benchmarked against Logistic Regression (LR) within a nested cross-validation pipeline to prevent data leakage. MICE imputation was performed strictly within the cross-validation folds. The independent external cohort (n = 50) was intentionally enriched (25 recurrence/25 no recurrence) to enable stable discrimination testing. Clinical utility was assessed via Decision Curve Analysis (DCA), and interpretability was established using SHapley Additive exPlanations (SHAP). Results: Median follow-up was 4.2 years. The Random Forest model outperformed Logistic Regression in both internal (ROC-AUC 0.704 vs 0.64) and external validation (ROC-AUC 0.71 vs 0.57). In internal out-of-fold analysis, the RF model achieved a sensitivity of 73.1% and specificity of 63.5% at a Youden-optimal threshold of 0.41. External validation demonstrated a consistent ROC-AUC of 0.71 (95% CI: 0.56–0.85). SHAP analysis identified tumor size, FEV1/FVC ratio, STAS, T-stage, and necrosis as the most influential predictors of recurrence. DCA showed superior net clinical benefit compared to "treat-all" or "treat-none" strategies. Conclusions: Our interpretable Random Forest model demonstrates stable discrimination and external validation using standard clinical data. This approach may support risk-adapted surveillance and guide postoperative decision-making, warranting prospective multicenter validation.
No takes yet. Share an insight, caveat, or question.
Kemik et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: